Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.58
QGEN's Cash to Debt is ranked higher than
51% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.07 vs. QGEN: 0.58 )
QGEN' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 0.58

Equity to Asset 0.61
QGEN's Equity to Asset is ranked higher than
67% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. QGEN: 0.61 )
QGEN' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.72
Current: 0.61

0.44
0.72
Interest Coverage 2.05
QGEN's Interest Coverage is ranked lower than
56% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. QGEN: 2.05 )
QGEN' s 10-Year Interest Coverage Range
Min: 2.05   Max: 53.96
Current: 2.05

2.05
53.96
F-Score: 4
Z-Score: 2.85
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.86
QGEN's Operating margin (%) is ranked higher than
74% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. QGEN: 4.86 )
QGEN' s 10-Year Operating margin (%) Range
Min: 4.86   Max: 23.8
Current: 4.86

4.86
23.8
Net-margin (%) 5.31
QGEN's Net-margin (%) is ranked higher than
76% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. QGEN: 5.31 )
QGEN' s 10-Year Net-margin (%) Range
Min: 5.31   Max: 15.62
Current: 5.31

5.31
15.62
ROE (%) 2.54
QGEN's ROE (%) is ranked higher than
68% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. QGEN: 2.54 )
QGEN' s 10-Year ROE (%) Range
Min: 2.54   Max: 19.67
Current: 2.54

2.54
19.67
ROA (%) 1.69
QGEN's ROA (%) is ranked higher than
70% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. QGEN: 1.69 )
QGEN' s 10-Year ROA (%) Range
Min: 1.69   Max: 12.23
Current: 1.69

1.69
12.23
ROC (Joel Greenblatt) (%) 9.69
QGEN's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. QGEN: 9.69 )
QGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.69   Max: 40.7
Current: 9.69

9.69
40.7
Revenue Growth (%) 6.00
QGEN's Revenue Growth (%) is ranked higher than
70% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. QGEN: 6.00 )
QGEN' s 10-Year Revenue Growth (%) Range
Min: 3.3   Max: 36.2
Current: 6

3.3
36.2
EBITDA Growth (%) -8.40
QGEN's EBITDA Growth (%) is ranked higher than
62% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. QGEN: -8.40 )
QGEN' s 10-Year EBITDA Growth (%) Range
Min: -8.4   Max: 40.6
Current: -8.4

-8.4
40.6
EPS Growth (%) -21.50
QGEN's EPS Growth (%) is ranked higher than
58% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. QGEN: -21.50 )
QGEN' s 10-Year EPS Growth (%) Range
Min: -21.5   Max: 44.2
Current: -21.5

-21.5
44.2
» QGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

QGEN Guru Trades in Q3 2013

PRIMECAP Management 17,881,461 sh (+60.33%)
Ron Baron 20,000 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc 6,269,758 sh (-0.53%)
» More
Q4 2013

QGEN Guru Trades in Q4 2013

Steven Cohen 9,222 sh (New)
PRIMECAP Management 19,385,944 sh (+8.41%)
Manning & Napier Advisors, Inc 6,290,930 sh (+0.34%)
Ron Baron 10,200 sh (-49%)
» More
Q1 2014

QGEN Guru Trades in Q1 2014

Jim Simons 1,028,319 sh (New)
PRIMECAP Management 22,234,504 sh (+14.69%)
Steven Cohen Sold Out
Ron Baron Sold Out
Manning & Napier Advisors, Inc 4,407,790 sh (-29.93%)
» More
Q2 2014

QGEN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 2,251,855 sh (-48.91%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Sold Out $20.46 - $24.82 $ 24.7910%0
Ron Baron 2013-12-31 Reduce -49%$20.63 - $24.65 $ 24.7910%10200
PRIMECAP Management 2013-09-30 Add 60.33%0.19%$19.72 - $21.88 $ 24.7919%17881461
PRIMECAP Management 2013-06-30 Add 22.63%0.06%$18.45 - $21.08 $ 24.7927%11152875
Ron Baron 2013-06-30 Reduce -45.95%$18.45 - $21.08 $ 24.7927%20000
PRIMECAP Management 2012-09-30 Add 31.89%0.06%$16.09 - $18.97 $ 24.7941%8579261
PRIMECAP Management 2012-06-30 New Buy0.18%$15 - $17.22 $ 24.7953%6504966
Ron Baron 2012-03-31 Add 26.98%$14.49 - $16.76 $ 24.7972%40000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 83.60
QGEN's P/E(ttm) is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 83.60 )
QGEN' s 10-Year P/E(ttm) Range
Min: 22.51   Max: 155.97
Current: 83.6

22.51
155.97
P/B 2.10
QGEN's P/B is ranked higher than
88% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.83 vs. QGEN: 2.10 )
QGEN' s 10-Year P/B Range
Min: 1.16   Max: 6.61
Current: 2.1

1.16
6.61
P/S 4.60
QGEN's P/S is ranked higher than
69% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. QGEN: 4.60 )
QGEN' s 10-Year P/S Range
Min: 2.71   Max: 6.54
Current: 4.6

2.71
6.54
PFCF 42.30
QGEN's PFCF is ranked higher than
82% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 42.30 )
QGEN' s 10-Year PFCF Range
Min: 19.41   Max: 185.83
Current: 42.3

19.41
185.83
EV-to-EBIT 82.29
QGEN's EV-to-EBIT is ranked higher than
74% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 82.29 )
QGEN' s 10-Year EV-to-EBIT Range
Min: 16.7   Max: 100.9
Current: 82.29

16.7
100.9
PEG 62.80
QGEN's PEG is ranked higher than
84% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 62.80 )
QGEN' s 10-Year PEG Range
Min: 1.39   Max: 64
Current: 62.8

1.39
64
Shiller P/E 48.40
QGEN's Shiller P/E is ranked higher than
90% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 48.40 )
QGEN' s 10-Year Shiller P/E Range
Min: 23.87   Max: 84.06
Current: 48.4

23.87
84.06
Current Ratio 3.88
QGEN's Current Ratio is ranked higher than
78% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. QGEN: 3.88 )
QGEN' s 10-Year Current Ratio Range
Min: 1.45   Max: 6.29
Current: 3.88

1.45
6.29
Quick Ratio 3.45
QGEN's Quick Ratio is ranked higher than
79% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. QGEN: 3.45 )
QGEN' s 10-Year Quick Ratio Range
Min: 1.18   Max: 5.75
Current: 3.45

1.18
5.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 59.00
QGEN's Price/Tangible Book is ranked higher than
59% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.75 vs. QGEN: 59.00 )
QGEN' s 10-Year Price/Tangible Book Range
Min: 2.94   Max: 106.38
Current: 59

2.94
106.38
Price/DCF (Projected) 1.70
QGEN's Price/DCF (Projected) is ranked higher than
89% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 1.70 )
QGEN' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 30.39
Current: 1.7

0.97
30.39
Price/Median PS Value 1.00
QGEN's Price/Median PS Value is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. QGEN: 1.00 )
QGEN' s 10-Year Price/Median PS Value Range
Min: 0.51   Max: 7.56
Current: 1

0.51
7.56
Price/Graham Number 14.50
QGEN's Price/Graham Number is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QGEN: 14.50 )
QGEN' s 10-Year Price/Graham Number Range
Min: 1.65   Max: 33.72
Current: 14.5

1.65
33.72
Earnings Yield (Greenblatt) 1.20
QGEN's Earnings Yield (Greenblatt) is ranked lower than
54% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. QGEN: 1.20 )
QGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 6
Current: 1.2

1
6
Forward Rate of Return (Yacktman) -3.42
QGEN's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.81 vs. QGEN: -3.42 )
QGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.1   Max: 26
Current: -3.42

-3.1
26

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0H1Z.UK, QIA.Germany
Qiagen NV is a provider of innovative technologies and products for pre-analytical sample preparation and linked molecular assay solutions. The company has developed a portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, and nucleic acid and protein handling, separation, and purification as well as open and target-specific assays. The Company also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. Products are sold to academic research markets, to pharmaceutical and biotechnology companies, to applied testing customers such as in forensics, veterinary, biodefense and industrial applications, as well as to molecular diagnostics laboratories. In addition, the Company sells and/or licenses technologies to others. Its products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. Sample technologies are used to collect, stabilize, isolate and purify molecules such as DNA, RNA and proteins from any biological sample. Sample technologies ensure that a sample is processed in a reproducible, standardized method with the highest level of quality before entering the subsequent analysis phase, for which the company provides a range of assay technologies, such as reagents and testing solutions. It also provides closed assays, in which the assay technologies have been pre-configured to test for specific targets such as the influenza virus, hepatitis, HIV, HPV or herpes. The main categories of its products include; Consumables, major applications for its consumable products are plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. Instrumentation: Automated systems offer walk-away automation of sample and assay technologies in low, medium or high throughput scale, as well as reaction set-up and other laboratory tasks.
» More Articles for NAS:QGEN

Headlines

Articles On GuruFocus.com
comment on QGEN May 14 2013 
comment on QGEN May 10 2013 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 


More From Other Websites
U.S. Stocks Little Changed After Fed Decision, GDP Data Jul 30 2014
Qiagen Reports In-line Earnings, Beats on Revenues in Q2 Jul 30 2014
QIAGEN reports second quarter and first half 2014 results and announces launch of new $100 million... Jul 30 2014
4:04 pm Qiagen beats by $0.01, reports revs in-line; guides Q3 EPS in-line; guides FY14 EPS below... Jul 29 2014
QIAGEN Reports Second Quarter and First Half 2014 Results and Announces Launch of new $100 Million... Jul 29 2014
QIAGEN and AstraZeneca collaborate to develop liquid biopsy-based companion diagnostic to advance... Jul 28 2014
AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests Jul 28 2014
QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance... Jul 28 2014
AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests Jul 28 2014
QIAGEN adds promising genomic biomarkers for assessing prognosis in treatment of blood cancers to... Jul 24 2014
QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to... Jul 24 2014
QIAGEN advances leadership in pre-analytical solutions for next-generation sequencing (NGS) with... Jul 16 2014
QIAGEN Advances Leadership in Pre-Analytical Solutions for Next-generation Sequencing (NGS) With... Jul 15 2014
Qiagen Is Next Deal Candidate With Tax Allure: Real M&A Jul 07 2014
Qiagen sees rare bullish activity Jun 23 2014
QIAGEN Receives FDA Approval of artus® CMV RGQ MDx Kit to Monitor Cytomegalovirus (CMV) Viral Load... Jun 18 2014
QIAGEN and Lilly Collaborate to Co-Develop Companion Diagnostics for Simultaneous Analysis of DNA... May 30 2014
Qiagen's therascreen KRAS Gets FDA Nod May 28 2014
Qiagen wins U.S. approval for test to accompany Amgen cancer drug May 23 2014
Amgen gets expanded approval for colon cancer drug May 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide